Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Payables (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Payables for 12 consecutive years, with $474000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 73.83% year-over-year to $474000.0, compared with a TTM value of $474000.0 through Sep 2025, down 73.83%, and an annual FY2024 reading of $283000.0, down 36.55% over the prior year.
  • Payables was $474000.0 for Q3 2025 at Avalo Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Payables topped out at $36.9 million in Q1 2022 and bottomed at $283000.0 in Q4 2024.
  • Average Payables over 5 years is $8.6 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Payables surged 1770.85% in 2021, then tumbled 95.6% in 2024.
  • Year by year, Payables stood at $3.4 million in 2021, then soared by 161.56% to $8.8 million in 2022, then plummeted by 94.94% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then skyrocketed by 67.49% to $474000.0 in 2025.
  • Business Quant data shows Payables for AVTX at $474000.0 in Q3 2025, $2.4 million in Q2 2025, and $681000.0 in Q1 2025.